

## Navinci and Lumito initiate pilot project – promising initial results from evaluation of combined technology

**Uppsala, Sweden – July 9, 2026** — Navinci Diagnostics AB ("Navinci") today announces that the Company has initiated a pilot project together with Lumito AB (publ) ("Lumito") to evaluate the possibilities of combining the companies' respective technologies within advanced tissue analysis.

The pilot project aims to combine Lumito's high-sensitivity image analysis platform with Navinci's *in situ* Proximity Ligation Technology (*isPLA*). By combining the strengths of both technologies, the ambition is to enable more sensitive and information-rich analyses of tissue samples, providing researchers with deeper biological insights.

Navinci's *in situ* Proximity Ligation Assay (*isPLA*) technology enables highly specific detection and quantification of proteins, protein-protein interactions, and post-translational modifications directly in tissue samples while preserving their spatial context. Lumito's core strength is its ultra-sensitive detection and imaging technology based on proprietary upconverting nanoparticles (UCNPs). Unlike conventional fluorescence methods, Lumito's technology generates signals with very low background noise and minimal interference enabling highly sensitive detection and quantification of biomarkers in tissue samples.

As a first step in the pilot project, Navinci has combined Lumito's SCIZYS Erbium kit together with its Naveni® *isPLA* technology, after which the samples were sent to Lumito for scanning in the company's SCIZYS scanner. The initial results have been jointly evaluated and are considered very promising, with high image quality. Work is now continuing with planning of the next steps.

*"We want Navinci's technology to work seamlessly with different imaging platforms, so it's very encouraging to see how well it performs together with Lumito's scanner. Navinci's platform allows researchers to study proteins and protein interactions directly in their tissue context, and Lumito's imaging technology adds impressive sensitivity and image quality. Seeing how easily the two technologies come together—and the quality of the results—reinforces the potential to support researchers in biomarker discovery and translational studies,"* said Jenny Sundqvist, CEO of Navinci.

*"We are very positive about the initial results. The combination of Lumito's sensitive detection platform and Navinci's established technology for precise detection of proteins and protein-protein interactions has the potential to create a powerful tool for researchers seeking to extract more information from complex biological samples. It is still an early-stage project, but*



*the initial results give us good reason to continue the evaluation",* says Sanna Wallenborg, CEO of Lumito.

**For further information, please contact:**

Jenny Sundqvist, CEO

E-mail: [jenny.sundqvist@navinci.se](mailto:jenny.sundqvist@navinci.se)

**About Navinci**

Navinci is a Swedish biotech company specializing in developing innovative solutions for studying *in situ* protein expression and interactions. With a focus and a strong legacy in developing *in situ* proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.